Scientists have designed new molecules that bind tightly to a specific site on Ras proteins in test tubes, blocking the interaction between Ras and Raf, which is a critical step in a cancer-promoting signaling pathway across multiple Ras mutations.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether reversible Ras inhibitors targeting the switch I-II pocket improve survival or tumor response in patients with KRas-mutant cancers across multiple clinical trials.
A systematic review and meta-analysis of all completed randomized controlled trials evaluating reversible Ras inhibitors targeting the switch I-II pocket in patients with advanced KRas-mutant solid tumors, comparing overall survival, progression-free survival, and objective response rates against standard chemotherapy or placebo, with standardized outcome definitions and risk-of-bias assessment.
Whether administration of these inhibitors improves clinical outcomes in patients with KRas-mutant cancers compared to standard therapy.
A double-blind, placebo-controlled phase II trial of 150 patients with advanced KRas-mutant non-small cell lung cancer or pancreatic cancer, randomized to receive oral dosing of the lead compound (e.g., 100 mg daily) or placebo for 24 weeks, with primary endpoint of progression-free survival by RECIST 1.1 and secondary endpoints of overall response rate and safety.
Whether exposure to these inhibitors in humans correlates with reduced tumor growth or prolonged survival in KRas-mutant cancers.
A prospective cohort study following 300 patients with KRas-mutant cancers who receive the inhibitor as part of compassionate use or early-access programs, measuring tumor burden via serial imaging, plasma biomarkers (e.g., pERK), and survival over 3 years, adjusting for prior therapies and mutation subtype.
Whether prior exposure to these inhibitors is associated with improved survival in patients with KRas-mutant cancers compared to matched controls.
A matched case-control study comparing 100 patients with KRas-mutant cancers who survived >24 months after diagnosis to 200 matched controls who died within 12 months, assessing whether any received the inhibitor during treatment, adjusting for age, stage, and prior therapies.
Whether patients treated with these inhibitors show lower levels of pERK in tumor biopsies compared to untreated patients.
A cross-sectional analysis of tumor biopsies from 50 patients with KRas-mutant cancers, comparing pERK levels by immunohistochemistry between those currently receiving the inhibitor and those who have never received it, matched for tumor type and mutation subtype.